SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Walker, S E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walker, S E
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Treatment of systemic lupus erythematosus with bromocriptine

S E Walker

Department of Internal Medicine, The University of Missouri-Columbia, Columbia, Missouri, USA

Prolactin, a lactogenic hormone, is a cytokine and an inportant link between the immune and endocrine systems. Prolactin stimulated disease in autoimmune NZB/NZW mice. Treatment of the mice with the prolactin-lowering dopamine agonist, bromocriptine, suppressed anti-DNA and prolonged life spans. These findings have been applied to humans with systemic lupus erythematosus (SLE). An open-label study, a double blind study, and a study comparing bromocriptine to hydroxychloroquine provided evidence that bromocriptine therapy reduced flares and suppressed disease activity in SLE.

Key Words: systemic lupus erythematosus • bromocriptine • prolactin

Lupus, Vol. 10, No. 3, 197-202 (2001)
DOI: 10.1191/096120301666625458
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J. Neurosci.Home page
A. Diogenes, A. M. Patwardhan, N. A. Jeske, N. B. Ruparel, V. Goffin, A. N. Akopian, and K. M. Hargreaves
Prolactin Modulates TRPV1 in Female Rat Trigeminal Sensory Neurons
J. Neurosci., August 2, 2006; 26(31): 8126 - 8136.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
V. Goffin, S. Bernichtein, P. Touraine, and P. A. Kelly
Development and Potential Clinical Uses of Human Prolactin Receptor Antagonists
Endocr. Rev., May 1, 2005; 26(3): 400 - 422.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
I Mendez, J Alcocer-Varela, A Parra, A Lava-Zavala, D A de la Cruz, D Alarcon-Segovia, and F Larrea
Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: a possible role of lymphocyte-derived prolactin
Lupus, January 1, 2004; 13(1): 45 - 53.
[Abstract] [PDF]

Home page
 Rheumatology (Oxford)Home page
R. H. Straub, J. Georgi, K. Helmke, P. Vaith, and B. Lang
In polymyalgia rheumatica serum prolactin is positively correlated with the number of typical symptoms but not with typical inflammatory markers
Rheumatology, April 1, 2002; 41(4): 423 - 429.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
S E Walker
Bromocriptine treatment of systemic lupus erythematosus
Lupus, October 1, 2001; 10(10): 762 - 768.
[Abstract] [PDF]


Advertisement